This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
16 Nov 2011

UCB & PAREXEL Team up for Clinical Services

Through the strategic partnership, UCB will receive the benefits of PAREXEL's proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform.

Biopharmaceutical services provider PAREXEL has been selected as one of two strategic partners by UCB, a global biopharmaceutical company, to provide clinical development services worldwide.

 

The agreement is effective for all of UCB's new clinical study programs on a global basis. Through the strategic partnership, UCB will receive the benefits of PAREXEL's proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform. UCB will also leverage PAREXEL's consulting expertise in regulatory affairs and commercialization.

 

PAREXEL will work with UCB to drive innovation and accelerate development, as well as to increase productivity and cost effectiveness.

 

Related News